UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
URGN POWR Grades
- Value is the dimension where URGN ranks best; there it ranks ahead of 72.88% of US stocks.
- URGN's strongest trending metric is Value; it's been moving up over the last 177 days.
- URGN ranks lowest in Momentum; there it ranks in the 4th percentile.
URGN Stock Summary
- UROGEN PHARMA LTD's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 5.45% of US listed stocks.
- URGN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 3.99% of US stocks.
- With a year-over-year growth in debt of 24,805.28%, UROGEN PHARMA LTD's debt growth rate surpasses 99.82% of about US stocks.
- Stocks that are quantitatively similar to URGN, based on their financial statements, market capitalization, and price volatility, are XOS, DRIO, ULBI, AXON, and ONDS.
- URGN's SEC filings can be seen here. And to visit UROGEN PHARMA LTD's official web site, go to www.urogen.com.
URGN Valuation Summary
- In comparison to the median Healthcare stock, URGN's price/sales ratio is 63.16% higher, now standing at 3.1.
- URGN's price/sales ratio has moved down 7.3 over the prior 72 months.
Below are key valuation metrics over time for URGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| URGN | 2023-03-24 | 3.1 | -2.2 | -1.8 | -2.4 |
| URGN | 2023-03-23 | 3.1 | -3.0 | -1.8 | -2.3 |
| URGN | 2023-03-22 | 3.0 | -3.0 | -1.7 | -2.3 |
| URGN | 2023-03-21 | 3.2 | -3.2 | -1.8 | -2.4 |
| URGN | 2023-03-20 | 3.1 | -3.1 | -1.8 | -2.4 |
| URGN | 2023-03-17 | 3.1 | -3.1 | -1.8 | -2.4 |
URGN's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- URGN has a Quality Grade of D, ranking ahead of 11.82% of graded US stocks.
- URGN's asset turnover comes in at 0.249 -- ranking 178th of 682 Pharmaceutical Products stocks.
- BIIB, TECH, and ZGNX are the stocks whose asset turnover ratios are most correlated with URGN.
The table below shows URGN's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.249 | 0.897 | -1.677 |
| 2021-03-31 | 0.148 | 0.901 | -1.535 |
| 2020-12-31 | 0.080 | 0.914 | -1.308 |
| 2020-09-30 | 0.023 | 0.907 | -1.202 |
| 2020-06-30 | 0.002 | 0.871 | -1.036 |
| 2020-03-31 | 0.000 | 1.000 | -0.926 |
URGN Price Target
For more insight on analysts targets of URGN, see our URGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $42.60 | Average Broker Recommendation | 1.33 (Strong Buy) |
URGN Stock Price Chart Interactive Chart >
URGN Price/Volume Stats
| Current price | $9.24 | 52-week high | $12.63 |
| Prev. close | $8.38 | 52-week low | $4.85 |
| Day low | $8.42 | Volume | 262,800 |
| Day high | $9.78 | Avg. volume | 114,390 |
| 50-day MA | $9.38 | Dividend yield | N/A |
| 200-day MA | $8.89 | Market Cap | 210.13M |
UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.
Latest URGN News From Around the Web
Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.
UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call TranscriptUroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript March 16, 2023 Operator: Good day and thank you for standing by. And welcome to the UroGen Pharma Q4 2022 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there’ll be a question-and-answer session. Please be advised that today’s […] |
Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue EstimatesUrogen Pharma (URGN) delivered earnings and revenue surprises of -8.93% and 0.87%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate DevelopmentsPRINCETON, N.J., March 16, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the fourth quarter and full year ended December 31, 2022, and overview of recent developments. |
UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023PRINCETON, N.J., March 09, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report fourth quarter and full-year 2022 financial results on Thursday, March 16, 2023, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. |
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PRINCETON, N.J., March 06, 2023--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units ("RSUs") to 7 new employees in connection with their entering into employment with UroGen. The grants were made between March 1, 2023 and March 6, 2023. These new team members will support the ongoing commercial launch of Jelmyto® (mitomycin |
URGN Price Returns
| 1-mo | -12.83% |
| 3-mo | 4.17% |
| 6-mo | 11.06% |
| 1-year | 6.08% |
| 3-year | -48.21% |
| 5-year | -81.40% |
| YTD | 4.17% |
| 2022 | -6.73% |
| 2021 | -47.23% |
| 2020 | -46.00% |
| 2019 | -22.50% |
| 2018 | 15.72% |
Loading social stream, please wait...